HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $28 to $44. This adjustment reflects a positive outlook on the company's future performance.
March 08, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revolution Medicines' Buy rating is maintained by HC Wainwright & Co., with a significant increase in price target from $28 to $44.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish outlook on the company, suggesting that the firm has high expectations for Revolution Medicines' future performance. This can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100